1 L Rodriguez-Rivera.Considerations on the concept of epilepsy[J].Rev Neurol,1999;28:1159-61
2 rKumar.Classification and the need to classify epilepsy[J].In-dian J Pediatr,2000;67:S4-11
3 Bell GS,SanderJW.The epidemiology of epilepsy:The size of problem[J].Seizure,2002,11:306-14
4 Oun A,Haldre S,Magi M.Prevalence of adult epilepsy in Esto-nia[J].Epilepsy Res,2003;8:171-81
5 Ducan JS.The promise of new antiepileptic drugs[J].BrJ Clin Pharmacol,2002;53:123-31
6 Selak I.Pregabalin (Pfizer)[J].CurrOpin Investig Drugs,2001;2:828-34
7 TaylorCP,Vartanian MG,Yuen PW.Potent and stereospecific anticonsultant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeledby tritatedgabapentin[J].Epilep-sy Res,1993;14:11-5
8 Whitworth TL,Quick MW.Upregulation of grama-aminobutyric acid transporterexpession:Role of alkylated aminobutyric acid derivatives[J].Biochem Soc Trans,2001;29:736-41
9 Hurley RW,Chatterjea D,Rose,Feng M.Gabapentin and Prega-balin can interact synergistically with naproxen to produce anti-hyperalgesia[J].Anesehesiology,2002;97:1263-76
10 Huppertz HJ,Feuerstein TJ,Schulze-Bonhage A.Myoclonus in epilepsy patients with anticonvulsive add-on therapy with prega-balin[J].Epilepsia,2001;42:790-2
11 CaterRB,Wood PL,Wieland S.Characterization of anticonvul-sant properties of ganaxolone(CCd1042;3α-hydroxy-3β-metyhl -5α-pregnan-20-one),a selective,high-affinity,steroid modulatorof the γ-aminobutyric acid receptor[J].J Pharmacol ExPTher,1997;280:1285-95
12 GasiorM,CaterRB,Goldberg SR.Anticonvulsant and behavior-al effects of nueroactive steroids alone and in conjunction with diazepam[J].J Pharmacol ExPTher,1997;282:543-53
13 GasiorM,Ungard JT,BeekmanM.Acute and chronic effects of the synthetic neuroactive steroid,ganaxolone,against the con-vulsive and lethal effects of pentylenetetrazol in seizure-kindled mice:Comparison with diazepam and volproate[J].Neurophar-macology,2000;39:1184-96
14 Reddy DS.NewerGABAergic agents forpharmacyotherapy of infantile spasms[J].Drugs Today,2002;38:657-75
15 Kaminski RM,Van Rijn CM,Turski WA.AMPA and GABAa receptorantagonist and theirinteraction an rats with a genetic form of absence epilepsy[J].EurJ Pharmacol,2001;430:251-9
16 Soudijn W,Wijingaarden I.The GABA transporterand its inhib-itors[J].CurrMed Chem,2000;15:339-50
17 Posson M,Huguet F,SavattierA.A new type of anticonvulsant,stiripentol.Pharmacological profile and neurochemical study[J].Arzneim Forsch Drug Res,1984;34:199-204
18 Chiron C,Marchand M,Tran A.Stiripentol in severe myoclonic epilepsy in infancy:A randomized placebo-controlled syndrome-dedicated trial.STICLO study group[J].Lancet,2000;356:1638-42
19 TranA,Rey E,Pons G.Influence of stiripentol on cytochrome P-450-mediatedmetabolic pathways in humans:Invitro and in vivo comparison and calculation of in vivo inhibiton constants[J].Clin Pharmacol Ther,1997;62:490-504
20 Abel MS,Kohli N.GABA-transaminase antisense oligo deoxynu-cleotide modulates cocaine-and pentylenetetrazol -induced sei-zures in mice[J].Metab Brain Dis,1999;14:253-63
21 Karle J.Antisense studies of brain GABAa receptors[J].Dan Med Bull,2002;49:130-44
22 Stavem K,Loge JH,Kassa S.Health status of people with epi-lepsy compared with a general reference population[J].Epilep-sia,2000;41:85-90
23 BialerM,Jonannessen SI,Kupferberg HJ.Progress report on new antiepileptic drugs:A summary of the sixth eilat conference(EILAT VI)[J].Epilepsy Res,2002;51:31-71
24 Gill R,Alanine A,Bourson A.Pharmacological characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-meth-yl-benzyl)-piperidin-4-ol),a novel subtype-selective N-methyl-D-aspartate antagonist[J].J Pharmacol ExPTher,2002;302:940-8
25 Sun L,Lin SS.The anticonvulsant SGB-017(ADCI)blocks volt-age-gated sodium channels in rat and human neurons:Coparison with carbamazepine[J].Epilepsia,2000;41:263-70
26 Prorok M,Castellino FJ.Structure-function relationships of the NMDA receptorantagonist conantokin peptides[J].CurrDrug Targets,2001;2:313-22
27 Jimenez EC,Donevan S,WalkerC.Conantokin-L,a new NMDA receptorantagonist:Determinates foranticonvulsant potency[J].Epilepsy Res,2002;51:73-80
28 Donevan SD,McCabe RT.Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors[J].Mol Pharmacol,2000;58:614-23
29 JansenM,Potschka H,Brandt C.Hydantoin substituted 4,6-di-chloroindole-2-carboxylic acids as legends with high affinity forglycine binding site of the NMDA receptor[J].J Chem Med,2003;46:64-73
30 Schmitz D,Gloveli T,Heinemann U.Effects of losigamone on synaptic potentials and spike frequency habituation in rat ento-rhinal cortex and hippocampal CA1 neurons[J].Neurosci Lett,1995;200:141-3
31 Srinivasan J,Richens A,Davies JA.The effect of losigamone(AO-33)on electrical activity and excitatory amino acid release in mouse cortical slices[J].BrJPharmacol,1997;122:1490-4
32 Gebhardt C,Breustedt JM,NoldnerM.The antiepileptic drug losigamone decreases the persistent Na+current in rat hipp-ocampal neurons[J].Brain Res,2001;920:27-31
33 BauerJ,Schwalen S.Topiramate (TopamaxTM)Pharmacologi-cal characteristics and current use in epilepsy treatment[J].Nervenarzt,2000;71:495-501
34 Stefan H,Wang Y,Kerling F.Therapeutic intensive seizure analysis (TISA)in presurgical evaluationof losigamone[J].Ac-ta Neurol Scand,2001;104:195-201
35 Tortorella A,Halonen T,Sanhibzada N.A crucial role of α-ami-no-3-hydroxy-5-methyl -isoxazole-4-propionic acid subtype of Glutamate receptors in piriform and perirhinal cortex forthe ini-tiation and propagation of limbic motorseizures[J].J Pharmacol ExPTher,1997;280:1401-5
36 Rogawski MA,Donevan SD.AMPA receptors in epilepsy and as targets forantiepileptic drugs[J].Adv Neurol,1999;79:947-63
37 Auberson YP.Compititive AMPA antagonism:A novel mecha-nism forantiepileptic drugs[J] ? Drugs Fut,2001;26:463-71
38 CzuczwarSJ,SwiaderM,KuzniarH.LY300164,a novel antago-nist of AMPA kainite receptors,potentiates the anticonvulsive activity of antiepileptic drugs[J].EurJ Pharmacol,1998;359:103-9
39 Borowicz KK,Kleinrok Z,CzucawarSJ.The AMPA kainite re-ceptorantagonist,LY300164,increases the anticonvulsant effects of diazepam[J].Arch Pharmacol,2000;361:629-35
40 Lodge D,Bond A,O' Naill MJ.Stereoselective effects of 2,3-benzodiazepines in vivo:Electrophysiology and neuroprotection studies[J].Neuropharmacology,1996;35:1681-8
41 Andrasi F.Talampanel[J].Drugs Fut,2001;26:754-6
42 Kohara A,Okada M,Tsutsumi R.In-vitro Characterization of YM872,a selective,potent and highly water-solubleα-amino-3-hydroxy-5-methylisoxazole-4-propionate receptorantagonist[J].J Pharm Pharmacol,1998;50:795-801
43 Ohno K,Tsutsumi R,Matsumoto N.Functional characterization of YM928,a novel non-competitive α-amino-3-hydroxy-5-meth-yl -4-isoxazolepropionic acid(AMPA)receptorantagonist[J].J Pharmacol ExPTher,2003;303:66-72
44 WeiserT,BrennerM,Palluk R.BIIr561 CL:A novel combined antagonist of α-amino-3-hydroxy-5-methyl -4-isoxazolepropionic acid receptors and voltage-dependent sodium channelswith anti-convulsive and neuroprotective properties[J].J Pharmacol ExPTher,1999;289:1343-9
45 Nickel B,Shandra A,Godlevsky L.Anticonvulsant activity of D-20443[J].Arch Pharmacol,1993;34:Abst R-142
46 Nickel B,Shandra A,Godlevsky L.Antiepileptic effects of a new drug:D-20443[J].Epilepsia,1993;34:Abst 95
47 Dailey JW,Cheong JH,Ko KH.Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats:Prediction of clinical response[J].Neurosci Lett,1995;195:77-80
48 ToberC,Rostock A,Rundfeldt C.D-23129:A potent anticon-vulsant in the amygdala kindling model of complex partial sei-zures[J].EurJ Pharmacol,1996;303:163-9
49 Cheney JA,WeisserJD,Bareyre FM.The maxi-K channel open-erBMS-204352 attenuates regional cerebral edema and neuro-logic motorimpairment afterexperimental brain injury[J].J Cereb Blood Flow Metab,2001;21:396-403
50 Jain KK.An assessment of rufinamide as an anti -epileptic in comparisonwith otherdrugs in clinical development[J].Expert Opin Invetig Drugs,2000;9:829-40
51 Palhagen S,CangerR,Henriksen O.Rufinamide:A double-blind,placebo-controlled proof of principle trial in patientswith epilepsy[J].Epilepsy Res,2001;43:115-24
52 Santangeli S,Sills GJ,Thompson GG.Na channel effects of remacemide and desglycinyl -remacemide in rat cortical synapto-somes[J].EurJ Pharmacol,2002;438:63-8
53 Fatope MO.Soretolide(Laboratories Biocodex)[J].CurrOpin Invetig Drugs,2001;2:824-7
54 aurizis JC,Madelmont JC,RapPM.Disposition and me-tabolism of 2,6-dimethyl-benzamide N-(5-methyl -3-isoxazolyl)(D2916)in male and female rats[J].Drugs Metab Dispos,1997;25:33-9
55 Fariello RG,Maj R,Marrari P.Acute behavioral and EEG ef-fects of NW-1015 on electrically-induced afterdischarge in con-sciousmonkeys[J].Epilepsy Res,2000;39:37-46
56 M Bialer,SI Johannessen,HJ Kupferberg,RH Levy,E Peruc-ca,T Tomson.Progress report on new antiepileptic drugs:a summary of the seventh eilat conference (EILAT VII)[J].Epi-lepsy Res,2004;61:1-48
57 Chazot PL.Safinamide(Newron Pharmaceuticals)[J].CurrOpin Invetig Drugs,2001;2:809-13
58 58 Parsons AA,Bingham S,Raval P.Tonabersat (SB-220453)a novel benzopyran with anticonvulsant properties attenuated tri-geminal nerve-induced neurovascularreflexes[J].BrJ Pharcol,1997;132:1549-57
59 Hadad S,BialerM.Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide[J].Biop-harm Drug Dispos,1997;18:557-66
60 Isoherrannen N,Woodhead JH,White HS.Anticonvulsant profile of valrocemide (TV1901):A new antiepileptic drug[J].Epilep-sia,2001;42:831-6
61 BialerM.Pharmacokinetic consideration in the design of betterand safernew antieileptic drugs[J].J Control Release,1999;62:187-92
62 Isoherrannen N,Yagen B,BialerM.New CNS-active drugs which are second-generation valproic acid:Can they lead to the development of a magic bullet[J] ?CurrOpinNeurol,2003;16:203-11
63 LabinerDM.DP-VPA (D-Pharm)[J].CurrOpin Inv,2002;3:921-3
64 Spadoni F,Hainsworth AH,Mercuri N.Lamotrigine derivatives and riluzole inhibit INaPin cortical neurons[J].Neuroreport,2002;13:1167-70
65 Vezzani A,Sperk G,Colmers WF.Neuropeptide Y:Emerging evidence fora functional role in seizure modulation[J].TiNs,1999;22:25-30
66 Mazarati A,Langel U,Bartfai T.Galanin:A endogenous anti-convulsant[J] ?Neuroscientist,2001;7:506-17
67 Perez J,Vezzani A,Givenni G.Functional effects of D-Phe-c-(Cys-Tyr-D-Trp-Lys-Val -Cys)-Trp-NH 2 and differential changes in somatostatin receptormessengerRNAs,binding sites and so-matostatin release in kainic acid-treated rats[J].Neuroscience,1995;65:1087-97
68 SaarK,Mazarati AM,Mahlapuu R.Anticonvulsant activity of a nonpeptide galanin receptoragonist[J].Proc Natl Acad Sci USA,2002;99:7136-41
69 Rudolf K,Eberlein W,Engel W.The first highly potent and se-lective non-peptide neuropeptide Y1 receptorantagonist:BIBP3226[J].EurJ Pharmacol,1994;271:R11-3
70 SchefferGL,ScheperRJ.Drug-resistance molecules:lessons from oncology[A].In:Mechanisms of drug resistance in epi-lepsy:lessons from oncology.Novartis foundation symposium[M].JohnWiley &Sons:Chichester,2002:19-31
71 Cordon-Cardo C,O' Brien JP,Casals D.Multidrug-resistance gene(P-glycoprotein)is expressed by endothelial cells at blood-brain barriersites[J].Proc NatlAcadSci USA ,1989;86:695-8
72 Lemaire M,BruelisauerA,Guntz P.Dose-dependent brain penetration of SDZ PSC 833,a novel multidrug resistance-re-versing cyclosporin,in rats[J].CancerChemotherPharmacol,1996;38:481-6
73 Dantzig AH,Shepard RL,Law KL.Selectivity of the multidrug resistance modulator,LY335979,forP-glycoprotein and effect on cytochrome P-450 activities[J].J Pharmacol ExPTher,1999;290:854-62
74 BialerM,Johannessen SI,Kupferberg HJ.Progress report on new antiepileptic drugs:A summary of the fifth eliat conference(ELIAT V)[J].Epilepsy Res,2001;43:11-58
75 Hovinga CA.Novel anticonsultant medications in development[J].Epert Opin Investig Drugs,2002;11:1387-406
76 LoscherW,Schmidt D.New horizons in the development of antiepileptic drugs[J].Epilepsy Res,2002;50:3-16 |
